Avitide raises Series C

What does Avitide do?

Avitide, is a biotech company which is dedicated to rapid discovery and development of on demand affinity purification products. The company develops customized biopharmaceutical affinity purification solutions for the biopharmaceutical industry with an industry leading discovery and development service timeline. This company reduces the timelines of process development, production costs, program risks by providing high resolution customized affinity purification solutions. It is dedicated to advancing its partners commercial manufacturing processes and clinical pipelines and with exclusive, rapid, and enabling affinity purification platform technology.

How much Avitide was funded?

Avitide raised $7.6M in Series C funding on August 6, 2015 from the investors Neomed Management (Lead), OrbiMed Advisors, SV Life Sciences, Borealis Ventures and Polaris Partners.

Previous funding

$3.4M in Venture round on June 9, 2014

What is next for Avitide?

Avitide plans to use the funding for accelerating the commercialization of its on-demand affinity purification platform, focusing on biopharmaceutical drug products which include array molecules such as enzymes, proteins, antibody based therapeutics, gene therapies, recombinant vaccines and biosimilars. The latest financing is expected to take the company to profits in the next 2 years.

More about Avitide

Avitide was founded in 2012. It has its headquarters in Lebanon, NH. Its technology is meant to purify complex biologic drugs in an efficient and speedy manner. Its technology enables the company’s partners in rapidly discovering and developing robust, scalable affinity purification solutions for the challenging biopharmaceutical products. The company lowers the program risks and radically improves the existing clinical timeframes and economics of commercial development and manufacturing of the bioprocesses. The company’s service and technology delivers an exclusive affinity resin which helps its partners in achieving faster bioprocess development timelines, lowering program risk and reduces the program risk and manufacturing costs by providing cost effective, highly specific affinity purification solutions.